Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is ...
Sanofi eyes investment of up to $1.6 bln in Germany, Handelsblatt says The U.S. Food and Drug Administration declined to approve Merck and Japan-based Daiichi Sankyo's lung cancer treatment ...
German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company ... other research groups at the BioMed X Institute in Heidelberg, Germany.
AstraZeneca Plc and Daiichi Sankyo Co. have voluntarily withdrawn an application for a lung cancer treatment in the European Union in a blow for the experimental drug. The two companies said ...
Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated mucin-1 (TA-MUC1) antibody, from Glycotope for $132.5m. The gatipotuzumab ...
Daiichi Sankyo's stock has dropped 25% since my last update due to disappointing clinical data from Dato-DXd studies, but upcoming read-outs in 2025 could drive a meaningful rebound. Dato-DXd ...
TOKYO & BASKING RIDGE, N.J., January 13, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property ...